Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Revascularisation in Patients with Cancer
Author(s): Miguel Nobre Menezes , Mamas A Mamas Added: 3 days ago

CV Disease in Special Populations

Intervention
ESC/EACTS Guidelines 2025 for VHD Address Patient Values
Author(s): Benoit Mores Added: 2 months ago

Anticoagulation
Targeted Lipid Control in Very-high-risk Indian Patients: Expert Insights
Author(s): Kausik Ray , Upendra Kaul , Srinivasa Rao , et al Added: 1 month ago

Guidelines & Statements
AHA 25: Beta-Blocker Therapy Post MI in Patients with Preserved LVEF
Author(s): Anna Meta Dyrvig Kristensen Added: 2 months ago
AHA Scientific Sessions 2025 – Dr Anna Meta Dyrvig Kristensen (Copenhagen University Hospital, Bispebjerg and Frederiksberg, DK) presents an individual patient data meta-analysis examining beta-blocker therapy after myocardial infarction in patients with preserved left ventricular ejection fraction.This comprehensive meta-analysis pooled individual patient data from five randomized controlled… View more

Heart Failure
Systematic Scoping on DOACS in NVAF Patients
Author(s): Shirley Siang Ning Tan , Wei Hong Lai , Lee Len Tiong , et al Added: 5 months ago

Anticoagulation

Electrophysiology & Arrhythmia
TMVR in Patients with Multivalvular Heart Disease with Dr Kimberly Holst
Author(s): Kimberly Holst Added: 2 months ago
Navigate the strategic complexities of transcatheter mitral valve replacement in multivalvular disease with Dr Kimberly HolstThis presentation, part of Women As One's comprehensive Structural Interventions track, provides a systematic framework for approaching multivalvular heart disease. The presentation establishes the foundational principle of strategic intervention sequencing in high-risk… View more

Intervention
ADA 25: MariTide Treatment for Obesity in Patients with or without T2D
Author(s): Harold Bays Added: 6 months ago
ADA 2025 - Once-monthly MariTide treatment demonstrates around 15% average weight reduction at 52 weeks in patients with obesity, with or without type 2 diabetes.We are joined by Dr Harold Bays (L-MARC Research Center, Louisville, US) to discuss a 52-week, placebo-controlled, phase 2 randomised study (NCT05669599) investigating the efficacy, safety and tolerability of different doses of once… View more

Cardiovascular Renal Metabolic
Prioritising Risk in CAD: A Patient-First Discussion on Antiplatelet Therapy
Author(s): Marco Valgimigli , Diana Gorog , Eliano Navarese , et al Added: 2 years ago
This on-demand version of the live roundtable, chaired by Prof Marco Valgimigli (Cardiocentro Ticino Institute, Lugano, CH), demonstrates how to prioritise bleeding and ischaemic risks in coronary arterial disease (CAD) management. Key opinion leaders Prof Diana Gorog (University of Hertfordshire, UK), Prof Felicita Andreotti (Gemelli University Hospital, Rome, IT) and Prof Eliano Navarese … View more

Anticoagulation
Atorvastatin and Ezetimibe in Patients with Acute Coronary Syndrome
Author(s): Mohammed Sallam , Hossameldin Hassan , Derek Connolly , et al Added: 1 year ago

Prevention & Chronic Conditions

MI/ACS
EMPA-KIDNEY: Empagliflozin in Patients with Chronic Kidney Disease
Author(s): William Herrington Added: 1 year ago
Long-term cardio-renal outcomes investigating empagliflozin (Boehringer Ingelheim) on kidney disease progression (KDP) or cardiovascular death in patients with pre-existing chronic kidney disease.In this short interview, Prof William Herrington (Nuffield Department of Population Health, University of Oxford, Oxford, UK) discusses the findings from EMPA-KIDNEY (NCT03594110).EMPA-KIDNEY is an… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic